

Serbian Biochemical Society

President: Marija Gavrović-Jankulović

Vice-president: Suzana Jovanović-Šanta

General Secretary: Isidora Protić-Rosić

Treasurer: Milica Popović

Scientific Board

Marija Gavrović-
Jankulović
Svetlana Dinić
Ario de Marco
Suzana Jovanović-
Šanta
Mario Gabričević
Vladimir Mihailović
Theodore G.
Sotiroudis

Natalija Polović
Andreja Rajković
Nataša Simin
Edvard Petri
Sanja Krstić
Željko Popović
Snežana Pantović
Milan Nikolić
Simeon Minić

Organization Committee

Ivan Spasojević
Tanja Ćirković
Veličković
Milica Popović
Aleksandra
Uskoković
Tijana Ćulafić
Isidora Protić-Rosić
Jovana Trbojević-Ivić
Milena Dimitrijević
Srđan Miletić

Proceedings

Editor: Ivan Spasojević

Technical support: Jovana Trbojević-Ivić, Milena Dimitrijević, Tijana Ćulafić

Cover design: Zoran Beloševac

Publisher: Faculty of Chemistry, Serbian Biochemical Society

Printed by: Colorgrafx, Belgrade

No of printed copies: 130

Serbian Biochemical Society
Twelfth Conference

International scientific meeting

September 21-23, 2023, Belgrade, Serbia

“Biochemistry in Biotechnology”

Cisplatin-naproxen conjugate free and loaded in SBA-15 indicate morphological changes and antitumor activity *in vivo* in mouse melanoma model

Teodora Komazec^{1*}, Ekatarina Mihajlović¹, Dijana Bovan¹, Sanja Mijatović¹, Ivana Predarska^{2,3}, Goran N. Kaluderović², Evamarie Hey-Hawkins³, Danijela Maksimović-Ivanić¹

¹Department of Immunology, Institute for Biological Research “Siniša Stanković” - National Institute of the Republic of Serbia, University of Belgrade, Serbia

²Department of Engineering and Natural Sciences, University of Applied Sciences, Merseburg, Germany

³Institute of Inorganic Chemistry, Faculty of Chemistry and Mineralogy, Leipzig University, Germany

*e-mail: teodora.komazec@ibiss.bg.ac.rs

Overexpression of cyclooxygenase (COX) and thus, prostaglandin E2 in numerous cancers justified COX inhibitors testing in cancer prevention or treatment¹. Conjugate molecules of COX inhibitors and common chemotherapeutic drugs, as well as their immobilization in nanoparticles that increases drug delivery and accumulation in tumor tissue, can potentially improve approaches in cancer therapy. Cisplatin-naproxen conjugate and corresponding SBA-15 counterpart decreased the viability of B16 cells. Enlarged and elongated cells with distinctly granular cytoplasm and the increased presence of lipid droplets were noticed after haematoxylin–eosin and Oil Red O staining of treated cultures. In addition, enormous nuclei and markedly heterochromatin foci were confirmed by PI staining indicating establishment of senescent state upon the treatment. Alongside, differentiation of melanoma cells toward melanocytes was demonstrated by elevated tyrosinase activity and presence of melanin, thus leading to reduced tumorigenic potential *in vivo*. In addition, cisplatin-naproxen conjugate and corresponding SBA-15 counterpart significantly reduced melanoma growth in C57BL/6 mice, with lesser signs of toxicity compared to cisplatin as a positive control. Strong antitumor potential of both, free and immobilized conjugates on mouse melanoma cells opens numerous possibilities for further research.

Acknowledgements

This study was supported by the Ministry of Science, Technological Development, and Innovation of the Republic of Serbia (Grant No. 451-03-47/2023-01/200007).

References

1. Kolawole OR, Kashfi K. NSAIDs and cancer resolution: New paradigms beyond cyclooxygenase. *Int J Mol Sci* 2022;23:1432.